Latest News and Press Releases
Want to stay updated on the latest news?
-
MARIETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following...
-
Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18...
-
MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third...
-
MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for...
-
Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga.,...
-
MARIETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following...
-
MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a...
-
Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted...
-
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first...
-
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second...